Uptake of liposome-encapsulated 99Tcm-MIBI by sensitive and multidrug-resistant tumour cell lines.
It is well established that accumulation of 99Tcm-sestamibi (99Tcm-MIBI) is much higher in sensitive than multidrug-resistant tumour cells expressing the permeability glycoprotein 170 (Pgp 170) as well as a multidrug-resistance related protein (MRP). Thus 99Tcm-MIBI is a good candidate for diagnosing the multidrug-resistance phenotype by in vivo imaging. However, the blood clearance of 99Tcm-MIBI is too rapid to achieve optimal accumulation in tumours and uptake in the liver, spleen, heart and muscle is too high for it to be an excellent in vivo tumour tracer. One way of prolonging the bioavailability of 99Tcm-MIBI is to use liposomes which do not affect its accumulation in tumour cells. We explored this possibility in vitro using two sensitive and five resistant cell lines, two of them expressing Pgp 170 and three others over-expressing MRP. 99Tcm-MIBI was incorporated into liposomes prepared by thin film hydration with phosphate-buffered saline using distearoyl phosphatidyl choline, distearoyl phosphatidyl ethanolamine and cholesterol in a ratio of 1.85:0.15:1.00. Liposome diameter was 97.9 +/- 4.5 nm as determined by dynamic light scattering. 99Tcm-MIBI uptake was quantified by measuring radioactivity retained in the cells incubated at 37 degrees C with liposome-encapsulated 99Tcm-MIBI or with free radiotracer in the presence of empty liposomes. In both experimental cases, 99Tcm-MIBI accumulation was similar to that obtained in the presence of free 99Tcm-MIBI only: it was much higher in sensitive than in resistant Pgp 170-positive and MRP-positive cells. Encapsulation in liposomes does not alter the potency of 99Tcm-MIBI to distinguish the sensitive and resistant tumour cells. Our results suggest that future studies should assess the usefulness of the encapsulated form of 99Tcm-MIBI for in vivo imaging of tumours.
Laboratoire de Radiopharmacologie UPRES 2360, Université Paris Nord, Bobigny, France.
M D
MD
Cordobes
J L
JL
Moretti
V
V
de Beco
F
F
Benazzouz
A
A
Starzec
D000230:Adenocarcinoma; D001692:Biological Transport; D001943:Breast Neoplasms; D018288:Carcinoma, Small Cell; D002784:Cholesterol; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D007700:Kinetics; D008081:Liposomes; D008175:Lung Neoplasms; D009062:Mouth Neoplasms; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017256:Technetium Tc 99m Sestamibi / Q000493:pharmacokinetics*; D014407:Tumor Cells, Cultured
D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D019275:Radiopharmaceuticals; C038089:1,2-distearoylphosphatidylethanolamine; D017256:Technetium Tc 99m Sestamibi; D002784:Cholesterol; C010942:1,2-distearoyllecithin